ASH - Imara GAAP EPS of -$2.37 beats by $0.21

Imara press release (NASDAQ:IMRA): FY GAAP EPS of -$2.37 beats by $0.21. Cash, cash equivalents and investments of $90.28M. CEO comment: "We are pleased to have expanded our pipeline with the addition of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2 (Nrf2). We reported robust data with IMR-261 in validated preclinical models of sickle cell disease and beta-thalassemia at the American Society of Hematology (NYSE:ASH) Annual Meeting in December 2021. We believe that IMR-261 also has the potential to work on several areas beyond hemoglobin disorders and we are actively exploring diseases of iron overload. It is exciting to add this clinic-ready asset to the pipeline and we look forward to providing further updates on study plans in 2022.”

For further details see:

Imara GAAP EPS of -$2.37 beats by $0.21